Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets - Biotech Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets - by Ben Adams

Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal - by John Carroll

Sosei finds second partner for muscarinic neurology assets in Neurocrine - by Stephen Hansen

Sosei, Neurocrine ink $2.6B neuropsychiatric collaboration - by Nuala Moran